Form 4: Sarepta Executive Granted 143,875 RSUs

Sarepta Therapeutics' President of R&D and Tech Ops, Louise Rodino-Klapac, received grants of 143,875 restricted stock units on September 3, 2025.

Summary

• Louise Rodino-Klapac, President, R&D and Tech Ops at Sarepta Therapeutics, Inc. (SRPT), was granted a total of 143,875 restricted stock units (RSUs) on September 3, 2025.
• One grant consisted of 93,875 RSUs, with 50% vesting on September 3, 2026, and the remaining 50% vesting on September 3, 2027, contingent on continued service.
• A second grant involved 50,000 RSUs, which will vest 100% on September 3, 2028, subject to both continued service and the achievement of specific performance criteria as determined by the Compensation Committee.
• The reporting person's beneficial ownership of common stock following these transactions is 228,612 shares.
• This total includes 106 shares of common stock purchased on August 31, 2025, through the Company's Employee Stock Purchase Plan.

Sentiment

Score: 7

Explanation: The filing indicates a positive event for the executive through significant equity grants, which is a routine and generally positive mechanism for executive retention and alignment of interests for the company.

Positives

• The grants of 143,875 restricted stock units serve as a significant incentive for executive retention and align management's interests with long-term shareholder value.
• The inclusion of performance criteria for a portion of the RSUs ties executive compensation directly to company performance, which can be viewed favorably by investors.

Risks

• The vesting of 50,000 RSUs is contingent on the achievement of certain performance criteria, which introduces a risk that the executive may not fully realize the value of this grant if those criteria are not met.
• All RSU grants are subject to the reporting person's continued service to the Company, meaning forfeiture if employment ceases before vesting dates.

Future Outlook

The future realization of the RSU grants is contingent upon Louise Rodino-Klapac's continued service to Sarepta Therapeutics and, for a portion of the grants, the achievement of specific performance criteria by September 3, 2028.

Industry Context

The granting of restricted stock units to key executives is a common practice in the biotechnology and pharmaceutical industries. It serves as a long-term incentive to retain talent and align executive interests with shareholder value, particularly in companies focused on research and development where long-term project cycles are prevalent.

Comparison to Industry Standards

• This type of equity grant, combining time-based and performance-based vesting, is a standard compensation structure for senior executives in the biotech sector, comparable to practices at companies like BioMarin Pharmaceutical Inc. or Vertex Pharmaceuticals Incorporated, which also utilize multi-year vesting schedules to incentivize long-term commitment and performance.

Stakeholder Impact

• Shareholders: The grants align the executive's financial interests with the long-term performance of the company, potentially fostering greater commitment to value creation.
• Employees: May signal the company's commitment to retaining key talent, potentially boosting morale and stability within the leadership team.

Next Steps

• Monitoring the vesting of the 93,875 RSUs on September 3, 2026, and September 3, 2027.
• Monitoring the achievement of performance criteria and subsequent vesting of the 50,000 RSUs on September 3, 2028.

Key Dates

Keywords

Sarepta Therapeutics, SRPT, Form 4, Insider Transaction, Restricted Stock Units, RSU, Stock Grant, Executive Compensation, Louise Rodino-Klapac